Synthego Corporation

Industrial Impact

ThinkCyte Inc. | July 12, 2022

ThinkCyte Inc., a biotechnology company pioneering novel cell analysis and sorting instruments, announced that applications of its Ghost Cytometry technology were presented at several leading industry meetings. In May, the company was selected to present applications of the platform to experts in drug discovery at the prestigious Keystone Symposia. The company was also selected to deliver a podium presentation at the 2022 International Association for the Advancement of Cytometry's annual me...

Medical

Pharmactive | June 08, 2022

Pharmactive Biotech Products, S.L.U., announces a new strategic partnership with Singapore-based Nutraconnect Pte, Ltd. to bring innovative, scientifically backed nutraceutical ingredients to the Asia-Pacific marketplace (not including Australia and New Zealand). The partnership will combine the strengths of both companies into a greater whole. Pharmactive will provide its well-supported, clean-label botanical extract ingredients, while Nutraconnect will function as a growth engin...

Industrial Impact

Riverside Partners | February 02, 2022

Syner-G BioPharma Group a leading provider of Chemistry, Manufacturing, and Controls technical, regulatory, and compliance consulting services to pharmaceutical and biotechnology clients, today announced the acquisition of Impact Pharmaceutical Services. Based in Research Triangle Park, NC, IMPACT supports the outsourced medical writing, regulatory strategy, and regulatory publishing and submission needs of biotech and pharma companies from pre-IND through post-marketing of drugs and biologics. ...

Industry Outlook

PRNewswire | June 15, 2023

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced today successful results of validation studies of the Tapestri® Platform. Data from a recently published white paper show how single-cell DNA sequencing technology could complement traditional bulk sequencing with the added advantage of detecting potential therapeutic resistance mutations. Drug developers must understand why some patients respond to therapies, while others do not,...